PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE
Growthpantoprazole sodium in 0.9% sodium chloride
NDAINTRAVENOUSSOLUTION
Approved
Feb 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE (pantoprazole sodium in 0.9% sodium chloride) by Baxter International is (h, k)-atpase enzyme system at the secretory surface of the gastric parietal cell. Approved for pathological hypersecretory conditions including zollinger-ellison (ze) syndrome in adults. First approved in 2024.
Drug data last refreshed 19h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pantoprazole sodium in 0.9% sodium chloride is an intravenous proton pump inhibitor (PPI) solution that binds to the (H, K)-ATPase enzyme system in gastric parietal cells to inhibit gastric acid secretion. It is indicated for pathological hypersecretory conditions including Zollinger-Ellison syndrome in adults. The drug provides sustained antisecretory effect lasting longer than 24 hours across all tested dose ranges.
Growth
Recently approved (Feb 2024) IV formulation in growth phase; commercial infrastructure is being built with moderate competitive pressure (30% intensity), suggesting opportunities for brand building and market establishment teams.
Mechanism of Action
(H, K)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. The binding to the (H, K)-ATPase results in a duration of antisecretory effect that persists longer…
Career Relevance
This recently approved IV formulation (Feb 2024) represents an early-stage growth opportunity with zero linked jobs currently, suggesting the brand team is still ramping. Working on this product means participating in market establishment, hospital formulary strategy, and acute-care positioning for a well-understood therapeutic class with moderate competition.
Worked on PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE at Baxter International? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.